Therapeutic studies progress on cardiovascular diseases by targeting mitochondrial damage
10.3760/cma.j.cn231583-20200409-00081
- VernacularTitle:基于线粒体靶点的心血管疾病干预研究进展
- Author:
Yingxue WANG
1
;
Shuqiu SUN
Author Information
1. 哈尔滨医科大学中国疾病预防控制中心地方病控制中心克山病防治研究所 150081
- From:
Chinese Journal of Endemiology
2020;39(12):933-936
- CountryChina
- Language:Chinese
-
Abstract:
Heart activity is highly dependent on adenosine triphosphate (ATP) produced via mitochondrial oxidative phosphorylation. Traditional therapeutics has developed drugs by repairing damaged mitochondrial DNA, reducing mitochondrial reactive oxygen species (ROS) production, and accelerating the degradation of damaged mitochondria and recycle. In recent years, however, mitochondrial replacement therapy has taken a different strategy, and has entered the clinical trial stage. This review will summarize the research progress of cardiovascular drugs targeting mitochondria and mitochondrial replacement therapy to provide a new perspective for addressing some relevant endemic diseases in China.
